|
|
Article: International Breast Cancer Prevention Study Launches in the United States and Canada; ExCel Research Study Seeks 4,500 Women to Participate in Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- March 30, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOSTON, March 30 /PRNewswire/ -- Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.
Coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), the ExCel research study will examine the potential benefit of exemestane and its ability to prevent breast cancer in women who are at increased risk for the disease. Exemestane -- part of a class of drugs called aromatase inhibitors -- suppresses estrogen ...